Myasthenia Gravis Market To Grow at a CAGR of 10.1% By 2025

Despite a largely consolidated vendor landscape with several large players and a few regional
players, competition in the global myasthenia gravis market is stiff. In this scenario, key players
hold small market shares. Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring,
Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda
Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc. are to name some
prominent companies in the global myasthenia gravis market. These companies are focused on
research and development for novel therapeutics for myasthenia gravis. This is one of the key
strategic moves adopted by companies operating in the myasthenia gravis market. Further, clinical
trials to introduce affordable therapeutics is also an important growth strategy of these companies.
According to a research report by Transparency Market Research (TMR), the global myasthenia
gravis market is anticipated to be worth US$2,313.1 mn by the end of 2025 from a valuation of
US$975.1 mn in 2016. During the forecast period of 2017 and 2025, the global myasthenia gravis
market is projected to clock a CAGR of 10.1%. The key treatment segments include cholinesterase
inhibitors, monoclonal antibodies, and chronic Immunomodulators. Among the key regional
segments, North America has emerged as a key market for myasthenia gravis on account of a
considerable prevalence of myasthenia gravis in the U.S.
Read Report @
Need to Prevent Deterioration of Life Quality due to Myasthenia Gravis Benefits Market
The rising prevalence of myasthenia gravis that can impact life quality is primarily driving the
myasthenia gravis market. Myasthenia gravis is an autoimmune disorder and neuromuscular
disorder that causes muscle weakness. The condition is characterized by fatigability and weakness
of skeletal muscles, wherein development follows respite. Muscles which are usually impacted are
the ones that monitor swallowing and breathing, eye movement, eye lids, and shoulder and facial
muscles. The condition affects muscles that a person can control consciously. The weakness of
muscles worsens with movement and improves with rest.
In myasthenia gravis, the muscle cells have difficulties to contract and respond to nerve impulses
which results in weakness of muscles.
Myasthenia gravis is initiated due to a decline in the number of postsynaptic acetylcholine receptors
at neuromuscular joints. This results in reduction of size of neuromuscular end-plate to
communicate the nerve signal. In a normal state, acetylcholine is released presynaptically in
response to a stimulus resultant in depolarization that results in muscle action. On the other hand, in
myasthenia gravis, the number of active postsynaptic receptors may be inadequate to trigger a
potential of muscle action. Further, with repeated stimulus, the decline in release of acetylcholine
correlates with fatigability.
Research and Development Initiatives to Fuel Growth
Nevertheless, myasthenia gravis usually does not impact life expectancy. Patients of myasthenia
gravis manage their symptoms and lead active lives. The condition is prevalent among people of all
ages and ethnicities. Typically, myasthenia gravis is prevalent among men of middle age and among
women between 20 to 30 years of age.
Research and development for therapeutics for myasthenia gravis is stoking growth of myasthenia
gravis market. Symptomatic and casual treatments are the key therapeutics for myasthenia gravis.
The symptomatic treatment involves increasing the duration of presence of acetylcholine, which is
responsible for transmitting the nerve impulse by antagonizing acetylcholinesterase.
The review presented here is based on the findings of a TMR report, titled “Global Myasthenia
Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and
Chronic Immunomodulators), Rapid Immunotherapies (Plasmapheresis, Intravenous
Immunoglobulin (IVlg)), and Thymectomy) - Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast, 2017–2025.”
Request Sample Report @